Physician profile
Roberto Hernandez Alejandro
NPI 1184179210
$524,222.28
in general payments reported to CMS, 2019-2025
7 companies · $520K in 2025
The $520K reported for 2025 was more than what 99% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $973 · 2022: $150 · 2023: $420 · 2024: $1,575 · 2025: $520K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $516K · Acquisitions: $2,621 · Travel and Lodging: $1,917 · Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $516,381.92 |
| Acquisitions | $2,620.89 |
| Travel and Lodging | $1,917.05 |
| Food and Beverage | $1,078.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $516,927.05 | 2024-2025 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $4,627.63 | 2025 | |
| Erbe Elektromedizin Gmbh | $1,860.23 | 2019-2020 | |
| Organ Recovery Systems, INC. | $453.07 | 2020-2023 | |
| Olympus America INC. | $280.77 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $50.00 | 2019 | |
| Gilead Sciences, INC. | $23.53 | 2024 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$58,750.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Hernandez Alejandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.